GC Biopharma, a South Korean biopharmaceutical company, announced on Feb. 10th that it presented development updates on its ...
AceLink is advancing a small-molecule treatment option for Fabry disease, which could provide a more convenient alternative ...
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions ...
Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme α-galactosidase A (GLA), which leads to complex multisystemic involvement, with the majority of patients ...
Zevra to receive a 2025 New Treatment Award for MIPLYFFAâ„¢ at the 21st Annual WORLDSymposiumEight abstracts discussing data and clinical ...
Families of rare disease patients appeal to PM Modi and Health Minister for increased treatment funding support.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback